Mobile website
Archive > Volume 21 Issue 3 > 2014,21(3):325-333. DOI:10.3872/j.issn.1007-385X.2014.03.016 Prev Next
Translational Medicine
Current status of bench-to-bedside translation of cancer therapeutic antibodies
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Antibody therapy has become the first-line treatment strategy for cancer patients. As of 2013, several antibodies including Cetuximab, Trastuzumab, Rituximab, Bevacizumab, and Ipilimumab have been approved by the Food and Drug Administration (FDA) of the United States for use in clinics to treat cancer patients. It is believed that use of cancer therapeutic antibodies in clinics is the most successful example of translational medicine. Moreover, development of novel cancer therapeutic antibodies has become the spotlight of research in recent years, and several potential antibodies, like MDX-1106 and BMS-936558 targeting PD-1, have entered into clinical trials. In this paper, we aim to review the performance the FDA-approved therapeutic antibodies targeting EGFR, HER2, CD20, VEGF, and CTLA-4 in clinical settings and the progress on the novel therapeutic antibodies under clinical trials.
Keywords:
Project Supported:
Project supported by the National Key Basic Research Development Program (973 Program)（No. 2013CB530500）, and the National Natural Science Foundation of China（No. 81172146）
Clc Number:
